Document is current
Any future updates will be listed below
-
Authors
Hennequart, Marc
Labuschagne, Christiaan F.
Tajan, Mylène
Pilley, Steven E. https://orcid.org/0000-0001-9670-3314
Cheung, Eric C.
Legrave, Nathalie M.
Driscoll, Paul C. https://orcid.org/0000-0002-4124-6950
Vousden, Karen H. https://orcid.org/0000-0002-7365-1766
-
Funding
Funding for this research was provided by:
Cancer Research UK (C596/A26855, C596/A26855)
Francis Crick Institute (FC001557, FC001557, FC001557, FC001557, FC001029, FC001029, FC001557, FC001029)
Wallonie-Bruxelles International Grant of Excellence
- License Information
-
More Information
Article History
Received: 28 August 2020
Accepted: 1 October 2021
First Online: 26 October 2021
Competing interests
: KHV is on the Board of Directors and shareholder of Bristol Myers Squibb and on the Science Advisory Board (with stock options) of PMV Pharma, RAZE Therapeutics and Volastra Therapeutics. She is also on the SAB of Ludwig Cancer. KHV is a co-founder and consultant of Faeth Therapeutics, funded by Khosla Ventures. She has been in receipt of research funding from Astex Pharmaceuticals and AstraZeneca and contributed to CRUK Cancer Research Technology filing of Patent Application WO/2017/144877. All other authors declare no competing interests.
